Patient-related risk factors appear to be the primary driver of readmissions in hospitals serving a higher proportion of minority patients, according to a study published online yesterday by the journal Surgery. The researchers examined outcomes and patient factors in more than 168,000 colorectal surgery patients treated in 374 California hospitals from 2004-2011, including 47 hospitals with a high percentage of minority patients (63%) compared with the other hospitals (17%). They found that patient factors (such as race, low income and insurance status) accounted for up to 65% of the increased odds for readmission at the minority-serving hospitals, while hospital-level factors (such as procedure volume and type) accounted for up to 40%. The Centers for Medicare & Medicaid Services’ Hospital Readmissions Reduction Program penalizes hospitals for higher-than-expected readmission rates for certain conditions, the authors note. “These findings suggest that CMS should account for patient socio-economic factors when they compare readmission rates,” said Waddah Al-Refaie, M.D., the study’s senior investigator and chief of surgical oncology at MedStar Georgetown University Hospital in Washington, D.C.

Headline
In this conversation, Amy Lee, president and chief operating officer at Nantucket Cottage Hospital, shares how telehealth is transforming patient care on the…
Headline
An executive order issued by the White House Oct. 19 directs the Department of Health and Human Services, through the National Institutes of Health, to…
Headline
The second listening session in the AHA’s series on disability health will focus on community partnerships and is scheduled for Oct. 28 at 1 p.m. ET. These…
Headline
In this conversation, Brian Peters, CEO of the Michigan Health & Hospital Association, explores the connection between health disparities, healthcare costs…
AHA Cyber Intel
While we may feel inundated with alarming news about escalating cyber threats against healthcare organizations, there is also some good news. Let’s explore how…
Headline
The Food and Drug Administration released draft guidance Sept. 24 that includes recommendations on non-clinical testing, clinical data and labeling for…